Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Opioid

or Research material

or [[:Category:DMARDs|DMARD]]

Use the filters below to narrow your results.

Other values:

5-HT2A agonist (26) · Monoamine releasing agent (9) · GABAA positive allosteric modulator (8) · CB1/CB2 agonist (7) · Potent mu-opioid receptor agonist (6) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Mu-opioid receptor agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Serotonin/norepinephrine/dopamine releasing agent (3) · None (2) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist (2) · Prodrug of GHB (2)

Other values:

None (160) · Mild to moderate pain; cough suppression (low-dose). (1) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-000007C1-QINU`"', '"`UNIQ--vote-000007C2-QINU`"', '"`UNIQ--vote-000007C3-QINU`"', '"`UNIQ--vote-000007C4-QINU`"', '"`UNIQ--vote-000007C5-QINU`"', '"`UNIQ--vote-000007C6-QINU`"', '"`UNIQ--vote-000007C7-QINU`"' (1) · '"`UNIQ--vote-000007E7-QINU`"', '"`UNIQ--vote-000007E8-QINU`"', '"`UNIQ--vote-000007E9-QINU`"', '"`UNIQ--vote-000007EA-QINU`"', '"`UNIQ--vote-000007EB-QINU`"' (1)

None (159) · 200-400 mg PO daily; '''dose by actual body weight ≤5 mg/kg/d''' to reduce retinopathy risk (AAO 2016 guideline) (1) · 40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1) · Adult: 15–60 mg every 4 hours as needed. (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) · Rheumatologic: 7.5-15 mg PO or SC '''once weekly''' (not daily — daily dosing is a recognized fatal error); folic acid 1 mg PO daily on non-MTX days; oncology dosing is far higher and indication-specific (1)

None (159) · 2.5 mg tablets; 10-50 mg/mL injection; pre-filled subcutaneous autoinjectors (Otrexup, Rasuvo); 2.5 mg/mL oral solution (Xatmep) (1) · 200 mg tablets; 100 mg/5 mL suspension (1) · 40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (159) · 360 mg/day (1) · 40 mg every week (selected indications); otherwise 40 mg every other week (1) · 400 mg/d typical maintenance; weight-adjusted ceiling per ophthalmology guidance (1) · N/A (never approved) (1) · Rheumatologic ~25 mg/week; oncology indication-specific (1)

None (159) · intramuscular (1) · intranasal; rectal and IV reported. (1) · intrathecal (1) · IV (1) · Oral (3) · PO (only formulation marketed in the US). (1) · subcutaneous (2) · sublingual (1)

None (159) · 30–60 min (PO) (1) · Rheumatologic effect at 4-8 weeks; ectopic resolution over 2-3 weeks (1) · Rheumatologic effect at 6-12 weeks (1) · Symptomatic effect within weeks; full response by 12-24 weeks (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (159) · 2 weeks per dose (1) · 4–6 hours (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · Once-weekly dosing in rheumatology (1) · Weeks (long half-life) (1)

None (159) · 2.5–3 hours (1) · 3-10 hours (low dose); 8-15 hours (high dose); much longer in third-space accumulation (pleural effusion, ascites)'"`UNIQ--ref-000007C8-QINU`"' (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~14 days'"`UNIQ--ref-00001103-QINU`"' (1) · ~40 days (terminal; reflects extensive tissue distribution)'"`UNIQ--ref-000007EC-QINU`"' (1)

None (159) · 60-70% PO at low doses; saturable at high doses (parenteral routes preferred above 15-25 mg/week)'"`UNIQ--ref-000007C9-QINU`"' (1) · 70-75% (oral)'"`UNIQ--ref-000007ED-QINU`"' (1) · Not formally characterized in humans. (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~64% from SC depot'"`UNIQ--ref-00001104-QINU`"' (1)

None (160) · '''Contraindicated in pregnancy''' (Category X); abortifacient and teratogenic. Discontinuation 3-6 months before conception is standard.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Long-considered safe in pregnancy for lupus and other rheumatologic indications; benefits typically outweigh.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (161) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (2)

Showing below up to 167 results in range #1 to #167.

1

2

3

4

5

7

7-Hydroxymitragynine

A

B

C

D

E

F

G

GBL

H

I

Isopropylphenidate

J

K

Kratom

L

M

N

O

P

R

S

T

U

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"